The searches "tesamorelin dosage for women", "sermorelin dosage for women" and their ipamorelin and CJC-1295 versions assume that a women's figure exists somewhere. For these four growth-hormone-releasing peptides, it does not. The labels and trials set one dose, sometimes per kilogram of body weight, for everyone they enrolled, and most of those enrolled were men. What the record does hold is a count of who was studied, one small trial that reported women separately, and the arithmetic of weight-based doses. This page sets those out from the labels and studies opened on 2026-10-28. It reports; it recommends no dose for anyone.
Each compound's full record is on its own page: tesamorelin, sermorelin, ipamorelin and CJC-1295.
The record by compound
| Compound | Labelled or studied dose | Dose set by sex? | Women in the record |
|---|---|---|---|
| Tesamorelin | Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily; original trials 2 mg daily | No | 10–16% of phase 3 participants (labels) |
| Sermorelin | Geref (discontinued): 30 mcg/kg nightly in children; analogue at 10 mcg/kg nightly in older adults | No | 10 of 19 in the one adult study that reported sex |
| Ipamorelin | 0.03 or 0.06 mg/kg intravenously, after bowel surgery | No | Both sexes enrolled; no result by sex found |
| CJC-1295 | 30 to 90 mcg/kg single or weekly doses in healthy adults | No | One study men only; the other's abstract does not state sex |
The CJC-1295 men-only study is Ionescu and Frohman (2006, 60 or 90 mcg/kg in men aged 20 to 40); the other, Teichman (2006), enrolled healthy adults aged 21 to 61 and its abstract gives no breakdown by sex.
Tesamorelin: one dose, mostly male trials
The two Egrifta labels state a single daily dose for adults with HIV and excess abdominal fat. Their clinical-studies sections describe who was in the trials: mean age 48, and 86% and 84% male in the two phase 3 studies, 88% and 90% male in the extensions. The waist-circumference entry criterion was the one place sex appeared in the design (a higher cut-off for men than women). Later academic trials enrolled "men and women": 50 adults with HIV and abdominal fat at 2 mg daily for six months (Stanley et al., JAMA 2014, PMID 25038357), and 39 obese adults with reduced GH secretion over twelve months (Makimura et al., PMID 24178787); neither abstract reports a result by sex.
The labels add one line that applies to women alone: tesamorelin is contraindicated in pregnancy, and the label gives the reason quoted in the fact block above.
Sermorelin: the one study that split the results
The adult evidence that reports women separately is a pair of papers from one 1997 trial. Ten women and nine men aged 55 to 71 self-injected placebo for four weeks, then a sermorelin analogue, [Nle27]GHRH(1-29)-NH2, at 10 micrograms per kilogram every night for 16 weeks (Khorram et al., PMID 9141536 and 9360512). Both sexes received the same per-kilogram dose. Nocturnal GH rose in women and men, IGF-I rose in both, and skin thickness increased in both. Lean body mass, insulin sensitivity, general well-being and libido improved in the men and not in the women. The authors concluded that the effects favoured men and that further studies were needed; the immune-system paper from the same trial found no sex difference. A 2013 review of GH in ageing explained its focus on men by stating that women "appear more resistant to treatment" (Sattler, PMID 24054930).
None of this is a women's dose. It is one dose, given to 19 people, with a different pattern of response by sex.
Ipamorelin and CJC-1295: weight, not sex
The ipamorelin trials gave 0.03 or 0.06 mg per kilogram intravenously after bowel surgery to patients of both sexes; the registry records enrol "all". The CJC-1295 studies dosed per kilogram as well. A per-kilogram rule gives a lighter person a smaller amount by design, which is the only sense in which these records give women and men different figures, and it is the same rule for both.
| Body weight | 10 mcg/kg (sermorelin analogue) | 30 mcg/kg (CJC-1295, Teichman) | 0.03 mg/kg (ipamorelin, IV trial) |
|---|---|---|---|
| 55 kg | 0.55 mg | 1.65 mg | 1.65 mg |
| 70 kg | 0.70 mg | 2.10 mg | 2.10 mg |
| 85 kg | 0.85 mg | 2.55 mg | 2.55 mg |
The clinic and vendor figures quoted on the compound pages (200 to 500 mcg of sermorelin nightly; 100 to 300 mcg of ipamorelin per injection) are flat amounts with no sex or weight term. A clinic article on sermorelin for women read on 2026-10-28 (Hone Health) gives no dose figure and says these peptides "are still being studied in women".
The amounts, as syringe units
Units on a U-100 syringe = milligrams ÷ concentration in mg/mL × 100.
| Amount | 2.5 mg/mL | 5 mg/mL | 10 mg/mL |
|---|---|---|---|
| 0.55 mg (10 mcg/kg at 55 kg) | 22 units | 11 | 5.5 |
| 0.70 mg (10 mcg/kg at 70 kg) | 28 | 14 | 7 |
| 1.28 mg (Egrifta WR label) | 51.2 | 25.6 | 12.8 |
| 1.4 mg (Egrifta SV label) | 56 | 28 | 14 |
| 2 mg (tesamorelin trials) | 80 | 40 | 20 |
2.5 mg/mL is a 5 mg vial with 2 mL of water; 5 mg/mL a 10 mg vial with 2 mL; 10 mg/mL a 10 mg vial with 1 mL. The tesamorelin vial arithmetic works any vial and volume, and tesamorelin vs sermorelin compares the two releasing peptides directly.
What is not established
A dose of any of these four peptides set for women: none exists in a label or trial read for this page. Whether women need a different amount: untested, since no trial randomised women to different doses. Results in premenopausal women: the one study that split by sex enrolled people aged 55 to 71. Use in pregnancy: contraindicated on the tesamorelin labels and unstudied for the others. Medibact's tesamorelin guide covers the compound. Decisions about whether to use any of them belong with a clinician.